Show simple item record

dc.contributor.authorAasbø, Gunvor
dc.contributor.authorTrope, Ameli
dc.contributor.authorNygård, Mari
dc.contributor.authorChristiansen, Irene Kraus
dc.contributor.authorBaasland, Ingrid
dc.contributor.authorIversen, Grete Alræk
dc.contributor.authorMunk, Ane Cecilie Dæhli
dc.contributor.authorChristiansen, Marit Halonen
dc.contributor.authorPresthus, Gro Kummeneje
dc.contributor.authorUndem, Karina
dc.contributor.authorBjørge, Tone
dc.contributor.authorCastle, Philip E.
dc.contributor.authorHansen, Bo Lars Thorvald Terning
dc.date.accessioned2023-05-04T08:31:16Z
dc.date.available2023-05-04T08:31:16Z
dc.date.created2022-09-06T11:30:21Z
dc.date.issued2022
dc.identifier.citationBritish Journal of Cancer. 2022, 127 (10), 1816-1826.
dc.identifier.issn0007-0920
dc.identifier.urihttps://hdl.handle.net/11250/3066120
dc.description.abstractBackground Cervical cancer screening participation is suboptimal in most settings. We assessed whether human papillomavirus (HPV) self-sampling may increase screening participation among long-term non-attenders in Norway. Methods A pragmatic randomised controlled trial with participation as the primary outcome was initiated in the national cervical screening programme in March 2019. A random sample of 6000 women aged 35–69 years who had not attended screening for at least 10 years were randomised 1:1:1 to receive either (i) a reminder to attend regular screening (control), (ii) an offer to order a self-sampling kit (opt-in) for HPV testing or (iii) a self-sampling kit unsolicited (send-to-all) for HPV testing. Results Total participation was 4.8%, 17.0% and 27.7% among control, opt-in and send-to-all (P < 0.0001; participation difference (%) send-to-all vs. control: 22.9 (95%CI: 20.7, 25.2); opt-in vs. control: 12.3 (95%CI: 10.3, 14.2); send-to-all vs. opt-in: 10.7 (95% CI: 8.0, 13.3)). High-risk HPV was detected in 11.5% of self-samples and 9.2% of clinician-collected samples (P = 0.40). Most women (92.5%) who returned a positive self-sample attended the clinic for triage testing. Of the 933 women screened, 33 (3.5%) had CIN2 + (1.1%, 3.7%, 3.8% among control, opt-in, and send-to-all, respectively), and 11 (1.2%) had cervical cancer (0%, 1.2%, 1.3% among control, opt-in, send-to-all, respectively). Conclusion Opt-in and send-to-all self-sampling increased screening participation among long-term, higher-risk non-attenders.
dc.language.isoeng
dc.titleHPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial
dc.title.alternativeHPV self-sampling among long-term non-attenders to cervical cancer screening in Norway: a pragmatic randomised controlled trial
dc.typePeer reviewed
dc.typeJournal article
dc.description.versionpublishedVersion
dc.source.pagenumber1816-1826
dc.source.volume127
dc.source.journalBritish Journal of Cancer
dc.source.issue10
dc.identifier.doi10.1038/s41416-022-01954-9
dc.identifier.cristin2049152
cristin.ispublishedtrue
cristin.fulltextoriginal
cristin.qualitycode2


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record